November 4, 2024 Dear Ambry Clients, Providers, Patients and Partners, On the heels of celebrating Ambry’s 25th Anniversary as a clinical genomics innovator and one of the country’s most trusted laboratory service providers, I am excited to share a new chapter in Ambry’s story. We have entered into a definitive agreement to be acquired by…

Enhanced hereditary cancer portfolio updates tests to reflect the latest scientific evidence and national consensus guidelines ALISO VIEJO, Calif., September 17, 2024 – Ambry Genetics, a leader in clinical genetic and genomic testing, today announced enhancements to their portfolio of tests for the detection of genetic mutations associated with hereditary cancer. This new evidence-informed menu…

ExomeReveal™ test expands Ambry Genetics’ clinical exome capabilities and applies its RNA analysis expertise to rare disease testing   ALISO VIEJO, Calif., August 19, 2024 – Ambry Genetics, a leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., today announced the ExomeReveal™ test, a new multiomic exome sequencing test designed to improve rare…

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif., May 15, 2024 /PRNewswire/ –Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today…

ALISO VIEJO, Calif. – March 12, 2024 – Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus, a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services. As part of the agreement, Ambry is performing germline…

Expanding the clinical use of RNA sequencing improves diagnostic yield, reduces inconclusive rates, and improves health equity ALISO VIEJO, Calif. – November 4, 2023 – Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics (ASHG) annual meeting results of a…

SINGAPORE and ALISO VIEJO, Calif. – April 19, 2023 – LifeStrands Genomics and Ambry Genetics have joined forces to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore’s National Precision Medicine (NPM) programme through an open tender commissioned by Precision…

GENEVA and ALISO VIEJO, Calif. – January 26, 2023 – Unilabs, a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx, have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research. Ambry…

Ambry’s digital CARE ProgramTM improves patient care by expanding access to carrier screening and non-invasive prenatal testing (NIPT).  ALISO VIEJO, Calif. – October 19, 2022 – Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx, launched a new reproductive health program that is driven by its CARE ProgramTM (Comprehensive Assessment…

The largest RNA study ever conducted in hereditary cancer analyzed more than 43,000 patients who received Ambry’s +RNAinsight™ testing and found that 1 in 950 had an elusive clinically actionable result that would have been missed by DNA-only testing. Combined DNA and RNA testing identified cancer risk in an additional 1 out of 79 patients…